Subscribe To
IMAB / Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage
IMAB News
By Seeking Alpha
September 13, 2023
I-Mab: Why This Company Trades At A Third The Value Of Its Cash
Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has more_horizontal
By Market Watch
June 27, 2023
Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage
A Chinese developer of cutting-edge cancer drugs has accused a chief competitor of stealing its trade secrets by posing as an expert witness in an arb more_horizontal
By Seeking Alpha
August 30, 2022
I-Mab (IMAB) H1 2022 Earnings Call Transcript
I-Mab (NASDAQ:IMAB ) H1 2022 Earnings Conference Call August 30, 2022 9:15 AM ET Company Participants Tyler Ehler – Senior Director of Investor Rela more_horizontal
By Seeking Alpha
June 23, 2022
I-Mab Valuation Offers A Biotech Investment Opportunity
The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotec more_horizontal
By Seeking Alpha
March 29, 2022
I-Mab (IMAB) CEO Management on Q4 2021 Results - Earnings Call Transcript
I-Mab (IMAB) CEO Management on Q4 2021 Results - Earnings Call Transcript more_horizontal
By PRNewsWire
March 18, 2022
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committ more_horizontal